These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7903933

  • 1. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
    Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, Girod C.
    Endocrinology; 1994 Jan; 134(1):401-10. PubMed ID: 7903933
    [Abstract] [Full Text] [Related]

  • 2. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
    Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A, Hooghe-Peters EL, Rousset B.
    Endocrinology; 1999 Jan; 140(1):13-21. PubMed ID: 9886801
    [Abstract] [Full Text] [Related]

  • 3. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [Abstract] [Full Text] [Related]

  • 4. Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma.
    Trouillas J, Girod C, Claustrat B, Joly-Pharaboz MO, Chevallier P.
    Cancer Res; 1990 Jul 01; 50(13):4081-6. PubMed ID: 2354457
    [Abstract] [Full Text] [Related]

  • 5. Transient dopaminergic inhibition of prolactin release from hybrid cells derived by fusion of normal rat pituitary and GH4C1 tumor cells.
    Day RN, Hinkle PM.
    Endocrinology; 1988 May 01; 122(5):2165-73. PubMed ID: 3129281
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May 01; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

  • 7. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 1996 Oct 01; 135(4):413-20. PubMed ID: 8921822
    [Abstract] [Full Text] [Related]

  • 8. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan 01; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 9. Characterization of long term hormonal cell cultures from the MtT/w15 prolactin- and growth hormone-secreting rat pituitary tumor.
    McKeel DW, Hajek SA.
    Endocrinology; 1981 Apr 01; 108(4):1571-86. PubMed ID: 7472284
    [Abstract] [Full Text] [Related]

  • 10. Time course of induction of prolactin-secreting pituitary tumors with diethylstilbestrol in male rats: response of tuberoinfundibular dopaminergic neurons.
    Morgan WW, Steger RW, Smith MS, Bartke A, Sweeney CA.
    Endocrinology; 1985 Jan 01; 116(1):17-24. PubMed ID: 3917247
    [Abstract] [Full Text] [Related]

  • 11. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M, Pagani G, Gianola D, Pagani MD, Salmoiraghi M, Ferrari L, Lancranjan I.
    J Clin Endocrinol Metab; 1986 Jul 01; 63(1):266-8. PubMed ID: 3711262
    [Abstract] [Full Text] [Related]

  • 12. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun 01; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V, Freneau E, Morange I, Simonetta C.
    Ann Endocrinol (Paris); 2000 Nov 01; 61(5):411-7. PubMed ID: 11084391
    [Abstract] [Full Text] [Related]

  • 14. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
    Winneker RC, Parsons JA.
    Cancer Res; 1981 May 01; 41(5):1772-7. PubMed ID: 7214344
    [Abstract] [Full Text] [Related]

  • 15. MtTW-10 pituitary tumor cells: galanin gene expression and peptide secretion.
    Hyde JF, Morrison DG, Moore JP, Howard G.
    Endocrinology; 1993 Dec 01; 133(6):2588-93. PubMed ID: 7694842
    [Abstract] [Full Text] [Related]

  • 16. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy.
    Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G, Figarella-Branger D.
    Cancer Res; 2000 Jan 01; 60(1):80-5. PubMed ID: 10646857
    [Abstract] [Full Text] [Related]

  • 17. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.
    Chiodini P, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Luccarelli G, Rainer E, Horowski R.
    J Clin Endocrinol Metab; 1981 Oct 01; 53(4):737-43. PubMed ID: 7287863
    [Abstract] [Full Text] [Related]

  • 18. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
    Eljarmak D, Lis M, Cantin M, Carrière PD, Collu R.
    Horm Res; 1985 Oct 01; 21(3):160-7. PubMed ID: 3997065
    [Abstract] [Full Text] [Related]

  • 19. Pure alpha-subunit-secreting mouse pituitary tumor: inhibition of growth and secretion by combined treatment with thyroxine and bromocriptine.
    Kieffer JD, Ross DS, Shupnik MA, Ridgway EC.
    Endocrinology; 1985 Oct 01; 117(4):1418-23. PubMed ID: 2411527
    [Abstract] [Full Text] [Related]

  • 20. Hyperprolactinemia after neonatal prolactin (PRL) deficiency in rats: evidence for altered anterior pituitary regulation of PRL secretion.
    Shah GV, Shyr SW, Grosvenor CE, Crowley WR.
    Endocrinology; 1988 May 01; 122(5):1883-9. PubMed ID: 3129278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.